Evidence map›Paper›PMID 37251391›Full record

ArticleFrontiers in immunology2023

Heterologous vaccination with inactivated vaccine and mRNA vaccine augments antibodies against both spike and nucleocapsid proteins of SARS-CoV-2: a local study in Macao.

Hoi Man Ng, Chon Lok Lei, Siyi Fu, Enqin Li, Sek In Leong, Chu Iong Nip, Nga Man Choi, Kai Seng Lai, Xi Jun Tang, Chon Leng Lei and 1 more

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.2field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. What we learned from lifting COVID-19 restrictions in Macao in December 2022.International journal of biological sciences · 2023
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Hoi Man NgLaboratory Department, Kiang Wu Hospital, Macao SAR, China.
Chon Lok LeiFaculty of Health Sciences, University of Macau, Macao SAR, China.
Siyi FuFaculty of Health Sciences, University of Macau, Macao SAR, China.
Enqin LiFaculty of Health Sciences, University of Macau, Macao SAR, China.
Sek In LeongLaboratory Department, Kiang Wu Hospital, Macao SAR, China.
Chu Iong NipLaboratory Department, Kiang Wu Hospital, Macao SAR, China.
Nga Man ChoiLaboratory Department, Kiang Wu Hospital, Macao SAR, China.
Kai Seng LaiLaboratory Department, Kiang Wu Hospital, Macao SAR, China.
Xi Jun TangLaboratory Department, Zhuhai Hospital of Integrated Traditional Chinese and Western Medicine, Zhuhai, China.
Chon Leng LeiLaboratory Department, Kiang Wu Hospital, Macao SAR, China.
Ren-He XuFaculty of Health Sciences, University of Macau, Macao SAR, China.
University of Macau · MOKiang Wu Hospital · CNZhuhai Hospital of Integrated Traditional Chinese and Western Medicine · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The mRNA vaccines (RVs) can reduce the severity and mortality of severe acute respiratory syndrome coronavirus (SARS-CoV-2). However, almost only the inactivated vaccines (IVs) but no RVs had been used in mainland China until most recently, and the relaxing of its anti-pandemic strategies in December 2022 increased concerns about new outbreaks. In comparison, many of the citizens in Macao Special Administrative Region of China received three doses of IV (3IV) or RV (3RV), or 2 doses of IV plus one booster of RV (2IV+1RV). By the end of 2022, we recruited 147 participants with various vaccinations in Macao and detected antibodies (Abs) against the spike (S) protein and nucleocapsid (N) protein of the virus as well as neutralizing antibodies (NAb) in their serum. We observed that the level of anti-S Ab or NAb was similarly high with both 3RV and 2IV+1RV but lower with 3IV. In contrast, the level of anti-N Ab was the highest with 3IV like that in convalescents, intermediate with 2IV+1RV, and the lowest with 3RV. Whereas no significant differences in the basal levels of cytokines related to T-cell activation were observed among the various vaccination groups before and after the boosters. No vaccinees reported severe adverse events. Since Macao took one of the most stringent non-pharmaceutical interventions in the world, this study possesses much higher confidence in the vaccination results than many other studies from highly infected regions. Our findings suggest that the heterologous vaccination 2IV+1RV outperforms the homologous vaccinations 3IV and 3RV as it induces not only anti-S Ab (to the level as with 3RV) but also anti-N antibodies (via the IV). It combines the advantages of both RV (to block the viral entry) and IV (to also intervene the subsequent pathological processes such as intracellular viral replication and interference with the signal transduction and hence the biological functions of host cells).

Indexed as

COVID-19Nucleocapsid ProteinsAntibodies, NeutralizingHumansMacaumRNA VaccinesSARS-CoV-2Vaccines, InactivatedAntibodies, NeutralizingmRNA VaccinesNucleocapsid ProteinsVaccines, Inactivatedantibodiesheterologous vaccinationsinactivated vaccineMacaomRNA vaccinenucleocapsid proteinsSARS-CoV-2spike proteins

Identifiers

PMID37251391
PMCPMC10213252
OpenAlexW4378745053

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.